# Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

> **NCT02375555** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 40 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Elotuzumab
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone
- **PROCEDURE:** Stem Cell Mobilization

## Key facts

- **NCT ID:** NCT02375555
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-07
- **Primary completion:** 2021-12-15
- **Final completion:** 2024-01-26
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02375555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02375555, "Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02375555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*